Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791973 · ClinicalTrials.gov registry record · Phase 4
Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00791973 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 15 participants.
The verdict
NCT00791973, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to help us to a better understanding of how nose and eye symptoms are related in patients with allergies.
Interventions
- DRUG Placebo
- DRUG fluticasone furoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791973
The ClinicalTrials.gov registry entry for NCT00791973 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00791973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791973 about?
NCT00791973 is a clinical study titled "Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen". The purpose of this study is to help us to a better understanding of how nose and eye symptoms are related in patients with allergies.
What is the current status of trial NCT00791973?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00791973?
The interventions under investigation include: Placebo (DRUG), fluticasone furoate (DRUG).
Who is sponsoring clinical trial NCT00791973?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.